Prostatic Diseases: Clinical Trials

117 trials for Prostatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 19 unknown, 16 recruiting, 11 active not recruiting. 117 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1117Completed 47, Unknown 19, Recruiting 16, Active not recruiting 11, Terminated 9, Withdrawn 8, Not yet recruiting 6, Enrolling by invitation 1

Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases

Trials (filtered) newest first · largest first

All 117 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer
Early Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center302026-10-012026-08-24
PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging
68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging, 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging - Prostate Cancer
Early Phase 1Active not recruitingThe First Affiliated Hospital of Soochow University302026-09-242026-11-12
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma
Early Phase 1Not yet recruitingLumina Pharmaceuticals Inc402026-09-012026-08-28
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
177Lu-FC516 - Prostate Cancer
Early Phase 1RecruitingFindCure Biosciences (ZhongShan) Co., Ltd.132026-08-312026-09-04
Preoperative Semaglutide Prior to Radical Prostatectomy
Semaglutide 2.4 mg - Prostate Cancer
Early Phase 1Not yet recruitingBanner Health202026-07-012026-07-27
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
[177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126 - Metastatic Breast Cancer, Metastatic Prostate Cancer
Early Phase 1RecruitingIntegrated Haematology and Oncology Network202026-05-282026-06-10
RET-Targeted Molecular Imaging Probes in Prostate Cancer
RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging - Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
Early Phase 1Active not recruitingXiangya Hospital of Central South University502026-04-032026-10-21
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy - Prostate Cancer
Early Phase 1Not yet recruitingZhongda Hospital942026-04-012026-04-08
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
⁶⁸Ga-FC516, ⁶⁸Ga-FC516 and ⁶⁸Ga-labeled prostate cancer-targeting tracer - Healthy Adult, Prostate Cancer
Early Phase 1RecruitingFindCure Biosciences (ZhongShan) Co., Ltd.102026-03-092026-09-09
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
161Tb-LNC1011 - Prostate Cancer
Early Phase 1Not yet recruitingPeking Union Medical College Hospital152026-01-012026-02-02
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Biopsy of Prostate, Biospecimen Collection, Computed Tomography - Prostate Carcinoma
Early Phase 1RecruitingJonsson Comprehensive Cancer Center302025-11-142026-03-10
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Apple Cider Vinegar - Prostate Cancer, Metabolic Syndrome
Early Phase 1RecruitingWestern University302025-07-022025-08-20
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Tirzepatide - Diabetes, Prostate Cancer
Early Phase 1RecruitingM.D. Anderson Cancer Center302025-07-022026-09-25
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
18F-rhPSMA-7.3 - Prostate Cancer
Early Phase 1WithdrawnUniversity of Alabama at Birmingham2025-04-302024-09-25
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) - mCRPC
Early Phase 1Active not recruitingShanghai Changzheng Hospital72025-03-102026-07-23
Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia
alpha receptor antagonist, Low dose Tranilast, High dose Tranilast - Prostatic Hypertrophy, Benign
Early Phase 1RecruitingYifeng Jing302025-01-202026-01-08
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
[18F]AlF-PSMA-N5, [18F]F-DCFPyL - Prostate Cancer, PET/CT
Early Phase 1RecruitingAnhui Provincial Hospital302024-12-192025-01-03
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
lutetium (177Lu) rhPSMA 10.1 and Pluvicto® - Metastatic Prostate Cancer
Early Phase 1TerminatedBlue Earth Therapeutics Ltd172024-10-312025-09-25
68Ga-NTA-476 Imaging in Prostate Cancer
68Ga-NTA-476 - Prostate Cancer
Early Phase 1CompletedMelbourne Theranostic Innovation Centre102024-09-132025-09-25
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
68Ga-AAZTA-NI-093 - Prostate Cancer (Adenocarcinoma)
Early Phase 1UnknownFirst Affiliated Hospital of Fujian Medical University102024-09-012024-09-25

Showing 20 of 117. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (108)  ·  Breast Neoplasms (11)  ·  Prostatic Hyperplasia (8)  ·  Neoplasm Metastasis (6)  ·  Neoplasms (6)  ·  Ovarian Neoplasms (4)  ·  Pancreatic Neoplasms (4)  ·  Urinary Bladder Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Colonic Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Uterine Cervical Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Carcinoma, Renal Cell (2)

Broader conditions

Genital Diseases (117)  ·  Genital Diseases, Male (117)  ·  Male Urogenital Diseases (117)  ·  Urogenital Diseases (117)  ·  Genital Neoplasms, Male (109)  ·  Neoplasms by Site (109)  ·  Urogenital Neoplasms (108)  ·  Neoplasms (103)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Breast Diseases (11)  ·  Skin Diseases (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)

Interventions

Magnetic Resonance Spectroscopy (9)  ·  gallium 68 PSMA-11 (8)  ·  2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (4)  ·  Specimen Handling (4)  ·  Positron Emission Tomography Computed Tomography (3)  ·  2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2)  ·  68Ga-DKFZ-PSMA-11 (2)  ·  Abiraterone Acetate (2)  ·  Botulinum Toxins, Type A (2)  ·  Finasteride (2)  ·  HhAntag691 (2)  ·  Radiation (2)  ·  Standard of Care (2)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2)  ·  bicalutamide (2)

Sponsors

Jonsson Comprehensive Cancer Center (6)  ·  Mayo Clinic (6)  ·  Peking Union Medical College Hospital (5)  ·  Anhui Provincial Hospital (4)  ·  National Cancer Institute (NCI) (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  First Affiliated Hospital of Fujian Medical University (3)  ·  Johns Hopkins University (3)  ·  M.D. Anderson Cancer Center (3)  ·  Northwestern University (3)  ·  University of Wisconsin, Madison (3)  ·  Affiliated Hospital of Jiangnan University (2)  ·  FindCure Biosciences (ZhongShan) Co., Ltd. (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  University of Colorado, Denver (2)

Countries

United States (72)  ·  China (23)  ·  Australia (3)  ·  Canada (3)  ·  United Kingdom (3)  ·  Egypt (2)  ·  Netherlands (2)  ·  Denmark (1)  ·  Georgia (1)  ·  Jamaica (1)  ·  Pakistan (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Chunjing Yu (3)  ·  Misop Han, M.D., M.S. (3)  ·  Qiang Xie (3)  ·  Jingsong Zhang, M.D., Ph.D. (2)  ·  Rahul Aggarwal, MD (2)  ·  Adriana Coletta (1)  ·  Ahmed M Abdelbary, md (1)  ·  Allan Pantuck, M.D. (1)  ·  Ashley E Ross (1)  ·  Benjamin Franc, MD (1)  ·  Celina Shirazipour, PhD (1)  ·  Cheng Cheng Wang, M.D Ph.D (1)  ·  Christos Kyriakopoulos, MD (1)

Results publications

PMID 21233180, PMID 22341813, PMID 24686526, PMID 24726923, PMID 27826729, PMID 28806263, PMID 28894899, PMID 29180633, PMID 29602821, PMID 32466781, PMID 33568190, PMID 36358643, PMID 37914976, PMID 38104131, PMID 38782459, PMID 39136560, PMID 39254446, PMID 39928105, PMID 40177325, PMID 41698328, PMID 41759531, PMID 41833067

NIH funding

P30CA015083 (2), N01CM37120 (1), P30CA006516 (1), P30CA006973 (1), P30CA042014 (1), P30CA060553 (1), P30CA072720 (1), R01CA151395 (1), R01CA211150 (1), R01CA214554 (1), R01CA218547 (1), R01CA238379 (1), R01CA300053 (1), R01DK083609 (1), R01EB017449 (1)